Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Fluzoparib in TP-53 Mutated Endometrial Cancer
NCT06413992Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- May 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fluzoparib in endometrial cancer (EC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started May 2024; status: recruiting.
02
Drugs
fluzoparib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT06413992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06413992.